175 related articles for article (PubMed ID: 30900133)
1. Tetrahydrocurcumin-loaded vaginal nanomicrobicide for prophylaxis of HIV/AIDS: in silico study, formulation development, and in vitro evaluation.
Mirani A; Kundaikar H; Velhal S; Patel V; Bandivdekar A; Degani M; Patravale V
Drug Deliv Transl Res; 2019 Aug; 9(4):828-847. PubMed ID: 30900133
[TBL] [Abstract][Full Text] [Related]
2. Layer-by-Layer Engineered Microbicide Drug Delivery System Targeting HIV-1 gp120: Physicochemical and Biological Properties.
Coulibaly FS; Ezoulin MJM; Purohit SS; Ayon NJ; Oyler NA; Youan BC
Mol Pharm; 2017 Oct; 14(10):3512-3527. PubMed ID: 28830144
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Phytopolyphenols for their gp120-CD4 Binding Inhibitory Properties by In Silico Molecular Modelling & In Vitro Cell Line Studies.
Mirani A; Kundaikar H; Velhal S; Patel V; Bandivdekar A; Degani M; Patravale V
Curr HIV Res; 2019; 17(2):102-113. PubMed ID: 31187713
[TBL] [Abstract][Full Text] [Related]
4. Topical delivery of tetrahydrocurcumin lipid nanoparticles effectively inhibits skin inflammation: in vitro and in vivo study.
Kakkar V; Kaur IP; Kaur AP; Saini K; Singh KK
Drug Dev Ind Pharm; 2018 Oct; 44(10):1701-1712. PubMed ID: 29938544
[TBL] [Abstract][Full Text] [Related]
5. Development and in vivo safety assessment of tenofovir-loaded nanoparticles-in-film as a novel vaginal microbicide delivery system.
Machado A; Cunha-Reis C; Araújo F; Nunes R; Seabra V; Ferreira D; das Neves J; Sarmento B
Acta Biomater; 2016 Oct; 44():332-40. PubMed ID: 27544812
[TBL] [Abstract][Full Text] [Related]
6. Multivalent benzoboroxole functionalized polymers as gp120 glycan targeted microbicide entry inhibitors.
Jay JI; Lai BE; Myszka DG; Mahalingam A; Langheinrich K; Katz DF; Kiser PF
Mol Pharm; 2010 Feb; 7(1):116-29. PubMed ID: 20014858
[TBL] [Abstract][Full Text] [Related]
7. Triple combination MPT vaginal microbicide using curcumin and efavirenz loaded lactoferrin nanoparticles.
Lakshmi YS; Kumar P; Kishore G; Bhaskar C; Kondapi AK
Sci Rep; 2016 May; 6():25479. PubMed ID: 27151598
[TBL] [Abstract][Full Text] [Related]
8. Development and in vitro evaluation of a vaginal microbicide gel formulation for UAMC01398, a novel diaryltriazine NNRTI against HIV-1.
Grammen C; Ariën KK; Venkatraj M; Joossens J; Van der Veken P; Heeres J; Lewi PJ; Haenen S; Augustyns K; Vanham G; Augustijns P; Brouwers J
Antiviral Res; 2014 Jan; 101():113-21. PubMed ID: 24269474
[TBL] [Abstract][Full Text] [Related]
9. pH-sensitive dual-preventive siRNA-based nanomicrobicide reactivates autophagy and inhibits HIV infection in vaginal CD4+ cells.
Yang S; Chen Y; Gu J; Harris A; Su RC; Ho EA
J Control Release; 2024 Feb; 366():849-863. PubMed ID: 38176469
[TBL] [Abstract][Full Text] [Related]
10. Clinical development of microbicides for the prevention of HIV infection.
D'Cruz OJ; Uckun FM
Curr Pharm Des; 2004; 10(3):315-36. PubMed ID: 14754390
[TBL] [Abstract][Full Text] [Related]
11. The rational design and development of a dual chamber vaginal/rectal microbicide gel formulation for HIV prevention.
Ham AS; Nugent ST; Peters JJ; Katz DF; Shelter CM; Dezzutti CS; Boczar AD; Buckheit KW; Buckheit RW
Antiviral Res; 2015 Aug; 120():153-64. PubMed ID: 26093158
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Safety Evaluation of HIV-1 gp120 Responsive Microbicide Delivery System in C57BL/6 Female Mice.
Coulibaly FS; Ezoulin MJM; Dim DC; Molteni A; Youan BC
Mol Pharm; 2019 Feb; 16(2):595-606. PubMed ID: 30525661
[TBL] [Abstract][Full Text] [Related]
13. Intravaginal practices and microbicide acceptability in Papua New Guinea: implications for HIV prevention in a moderate-prevalence setting.
Vallely A; Fitzgerald L; Fiya V; Aeno H; Kelly A; Sauk J; Kupul M; Neo J; Millan J; Siba P; Kaldor JM
BMC Res Notes; 2012 Nov; 5():613. PubMed ID: 23116431
[TBL] [Abstract][Full Text] [Related]
14. Curcuminoid-loaded poly(methyl methacrylate) nanoparticles for cancer therapy.
Sahu A; Solanki P; Mitra S
Int J Nanomedicine; 2018; 13(T-NANO 2014 Abstracts):101-105. PubMed ID: 29593406
[TBL] [Abstract][Full Text] [Related]
15. Self-emulsifying drug delivery systems: Design of a novel vaginal delivery system for curcumin.
Köllner S; Nardin I; Markt R; Griesser J; Prüfert F; Bernkop-Schnürch A
Eur J Pharm Biopharm; 2017 Jun; 115():268-275. PubMed ID: 28323109
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of epithelial transport and oxidative stress protection of nanoengineered curcumin derivative-cyclodextrin formulation for ocular delivery.
Maharjan P; Jin M; Kim D; Yang J; Maharjan A; Shin MC; Cho KH; Kim MS; Min KA
Arch Pharm Res; 2019 Oct; 42(10):909-925. PubMed ID: 31030375
[TBL] [Abstract][Full Text] [Related]
17. Carboxymethylcellulose-tetrahydrocurcumin conjugates for colon-specific delivery of a novel anti-cancer agent, 4-amino tetrahydrocurcumin.
Plyduang T; Lomlim L; Yuenyongsawad S; Wiwattanapatapee R
Eur J Pharm Biopharm; 2014 Oct; 88(2):351-60. PubMed ID: 24859389
[TBL] [Abstract][Full Text] [Related]
18. Heterosexual anal intercourse has the potential to cause a significant loss of power in vaginal microbicide effectiveness studies.
McGowan I; Taylor DJ
Sex Transm Dis; 2010 Jun; 37(6):361-4. PubMed ID: 20514687
[TBL] [Abstract][Full Text] [Related]
19. Hansen solubility parameters (HSP) for prescreening formulation of solid lipid nanoparticles (SLN): in vitro testing of curcumin-loaded SLN in MCF-7 and BT-474 cell lines.
Doktorovova S; Souto EB; Silva AM
Pharm Dev Technol; 2018 Jan; 23(1):96-105. PubMed ID: 28949267
[TBL] [Abstract][Full Text] [Related]
20. In Silico Identification of Novel Aromatic Compounds as Potential HIV-1 Entry Inhibitors Mimicking Cellular Receptor CD4.
Andrianov AM; Nikolaev GI; Kornoushenko YV; Xu W; Jiang S; Tuzikov AV
Viruses; 2019 Aug; 11(8):. PubMed ID: 31412617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
